Cargando…
Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many advantages over HER2-CAR-T cells. Endogenous s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094803/ https://www.ncbi.nlm.nih.gov/pubmed/37047817 http://dx.doi.org/10.3390/ijms24076843 |
_version_ | 1785023928972869632 |
---|---|
author | Xia, Wenjiao Chen, Jiaxin Hou, Wenqing Chen, Junsheng Xiong, Ying Li, Hongyan Qi, Xin Xu, Hui Xie, Zuoquan Li, Mingfeng Zhang, Xiaomin Li, Jing |
author_facet | Xia, Wenjiao Chen, Jiaxin Hou, Wenqing Chen, Junsheng Xiong, Ying Li, Hongyan Qi, Xin Xu, Hui Xie, Zuoquan Li, Mingfeng Zhang, Xiaomin Li, Jing |
author_sort | Xia, Wenjiao |
collection | PubMed |
description | A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many advantages over HER2-CAR-T cells. Endogenous soluble PD-1 (sPD-1) from the PD-1 extracellular domain blocks PD-1/PD-L1 interaction to promote cancer immunology. Herein, we engineered a new HER2-CAR-NK cell that co-expresses sPD-1 (designed as sPD-1-CAR-NK cells) and assessed its cytotoxic activities toward various cancer cells, activation of immunity and sPD-1 release in vitro and in mouse models bearing breast cancer cells with high HER2 expression, with or without trastuzumab resistance. We demonstrated that sPD-1-CAR-NK cells were able to release bioactive sPD-1, thereby enhancing the cytolytic activities of HER2-CAR-NK cells against HER2 and PD-L1 highly expressing target cells accompanied by increases in the secretion of perforin, granzyme B and IFN-γ. In vivo, sPD-1-CAR-NK cells had superior immunological anticancer efficacy compared to HER2-CAR-NK cells, and they had advantages over HER2-CAR-NK cells in the intraperitoneal injection of sPD-1. Moreover, the infiltration and activation of NK and T cells into tumor tissue were increased in mice with sPD-1-CAR-NK cells. There was no significant change in the body temperature, organ tissue and body weight in all groups except for the group with the PD-1 injection. Together, these data indicate that HER2-specific sPD-1-CAR-NK cells can transport sPD-1 into cancer tissues with high HER2 expression, further improving the efficacy of HER-CAR-NK cells without obvious side effects. sPD-1-CAR-NK is a promising cytotherapeutic agent for patients bearing HER2-positive breast cancer, including those with trastuzumab resistance. |
format | Online Article Text |
id | pubmed-10094803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100948032023-04-13 Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy Xia, Wenjiao Chen, Jiaxin Hou, Wenqing Chen, Junsheng Xiong, Ying Li, Hongyan Qi, Xin Xu, Hui Xie, Zuoquan Li, Mingfeng Zhang, Xiaomin Li, Jing Int J Mol Sci Article A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many advantages over HER2-CAR-T cells. Endogenous soluble PD-1 (sPD-1) from the PD-1 extracellular domain blocks PD-1/PD-L1 interaction to promote cancer immunology. Herein, we engineered a new HER2-CAR-NK cell that co-expresses sPD-1 (designed as sPD-1-CAR-NK cells) and assessed its cytotoxic activities toward various cancer cells, activation of immunity and sPD-1 release in vitro and in mouse models bearing breast cancer cells with high HER2 expression, with or without trastuzumab resistance. We demonstrated that sPD-1-CAR-NK cells were able to release bioactive sPD-1, thereby enhancing the cytolytic activities of HER2-CAR-NK cells against HER2 and PD-L1 highly expressing target cells accompanied by increases in the secretion of perforin, granzyme B and IFN-γ. In vivo, sPD-1-CAR-NK cells had superior immunological anticancer efficacy compared to HER2-CAR-NK cells, and they had advantages over HER2-CAR-NK cells in the intraperitoneal injection of sPD-1. Moreover, the infiltration and activation of NK and T cells into tumor tissue were increased in mice with sPD-1-CAR-NK cells. There was no significant change in the body temperature, organ tissue and body weight in all groups except for the group with the PD-1 injection. Together, these data indicate that HER2-specific sPD-1-CAR-NK cells can transport sPD-1 into cancer tissues with high HER2 expression, further improving the efficacy of HER-CAR-NK cells without obvious side effects. sPD-1-CAR-NK is a promising cytotherapeutic agent for patients bearing HER2-positive breast cancer, including those with trastuzumab resistance. MDPI 2023-04-06 /pmc/articles/PMC10094803/ /pubmed/37047817 http://dx.doi.org/10.3390/ijms24076843 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xia, Wenjiao Chen, Jiaxin Hou, Wenqing Chen, Junsheng Xiong, Ying Li, Hongyan Qi, Xin Xu, Hui Xie, Zuoquan Li, Mingfeng Zhang, Xiaomin Li, Jing Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy |
title | Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy |
title_full | Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy |
title_fullStr | Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy |
title_full_unstemmed | Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy |
title_short | Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy |
title_sort | engineering a her2-car-nk cell secreting soluble programmed cell death protein with superior antitumor efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094803/ https://www.ncbi.nlm.nih.gov/pubmed/37047817 http://dx.doi.org/10.3390/ijms24076843 |
work_keys_str_mv | AT xiawenjiao engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT chenjiaxin engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT houwenqing engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT chenjunsheng engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT xiongying engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT lihongyan engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT qixin engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT xuhui engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT xiezuoquan engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT limingfeng engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT zhangxiaomin engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy AT lijing engineeringaher2carnkcellsecretingsolubleprogrammedcelldeathproteinwithsuperiorantitumorefficacy |